Loading

logo

Archives of Gastroenterology Research

ISSN: 2692-5427

Case Series Open Access

Risankizumab Demonstrates Clinical and Biochemical Effectiveness in Inflammatory Bowel Disease: A Retrospective Observational Study

Chamith H. Gunaratne1, Tausif Hussain2,*, Anas Hatab3, Joseph Collum4
  • 1Foundation Year 2 Doctor, Department of Gastroenterology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom
  • 2Internal Medicine Trainee Year 3, Department of Gastroenterology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom
  • 3Internal Medicine Trainee Year 1, Department of Gastroenterology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom
  • 4Consultant, Department of Gastroenterology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom
+ Affiliations - Affiliations

Corresponding Author

Tausif Hussain, Tausif.hussain@elht.nhs.uk

Received Date: November 17, 2025

Accepted Date: December 27, 2025

Citation:

Gunaratne CH, Hussain T, Hatab A, Collum J. Risankizumab Demonstrates Clinical and Biochemical Effectiveness in Inflammatory Bowel Disease: A Retrospective Observational Study. Arch Gastroenterol Res. 2026;7(1):1–7.


Copyright: © 2026 Gunaratne CH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Aim: To evaluate the real-world safety and effectiveness of risankizumab in patients with inflammatory bowel disease (IBD), using clinical outcomes and faecal calprotectin (FCP) as markers of response.

Methods: A retrospective observational study was conducted at East Lancashire Hospitals NHS Trust. Patients with a confirmed diagnosis of IBD who were initiated on risankizumab were included. Clinical outcomes, FCP levels, and treatment tolerability were assessed. As FCP values were non-normally distributed (Shapiro–Wilk p < 0.05), the Wilcoxon signed-rank test was used to compare pre-and post-treatment values.

Results: Thirty-two patients who were started on risankizumab treatment were analysed. Paired FCP data were available for 14 patients. Median FCP levels decreased from 1368.5 µg/g (range 146–2100) before treatment to 368 µg/g (range 52–2100) after treatment. The Wilcoxon signed-rank test demonstrated a statistically significant reduction in FCP following risankizumab therapy (Z=–2.201, p=0.028). Overall, 87.5% of patients reported clinical improvement and continued treatment. No adverse effects were reported while on therapy.

Conclusions: From this study, we conclude that risankizumab appears to be an effective and well-tolerated treatment option for patients with IBD.

Keywords

Risankizumab, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Biologic therapy, Real-world study, Monoclonal antibody, Gastroenterology

Recommended Articles

IL-10 Responsiveness and Anti-TNF Therapy in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a multifactorial disease in which both genetic and environmental factors play an important role, although the precise cause remains obscure. It is clear that both the innate and adaptive immunity are involved in acquiring mucosal immune homeostasis in the intestine, which is dysregulated in IBD.

Immune Cells and Transcriptional Signatures Revealed Novel Regulators and Predict Clinical Response to Biologic Therapy in Ulcerative Colitis

Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), has a heterogeneous pathogenesis underlined by genetic predisposition, intestinal barrier dysfunction, impaired immune response, and microbiota imbalance. This proceeds to aberrant immune cells presence and function in the affected tissue, activation of signaling pathways, and expression of regulators that subsequently drive inflammation.

Use of second Anti-Tumour Necrosis Factor Agent in Inflammatory Bowel Disease When First Agent Failed: A South African Retrospective Study

Inflammatory bowel disease is a chronic relapsing and remitting inflammation of the bowel. Tumour necrosis factor α - antagonists are safe and effective in the treatment of inflammatory bowel disease. Indications and outcomes with consecutive anti-tumour necrosis factor agents, although often used, are not clear. Since data for this treatment choice is scarce, we set out to evaluate the use of consecutive anti-tumour necrosis factor agents in patients with inflammatory bowel disease.

Preliminary Evidence of Differentially Induced Immune Responses by Microparticle-adsorbed LPS in Patients with Crohn’s Disease

Inorganic microparticles are ubiquitous in the modern Western diet present as food additives and are actively scavenged by microfold (M) cells overlying human intestinal lymphoid aggregates. In Crohn’s disease (CD), inflammation is caused by the inability of the intestinal mucosa to sustain tolerance to gut luminal factors including bacteria and their by-products.

Neurofibromatosis Type 1 and Crohn’s Disease Association: Case Report

We described a 15-year-old- a boy who presented with neurofibromatosis type 1 and Crohn’s disease. Neurofibromatosis 1 (NF1) is the most common form of NF, affecting 1 in 3000 individuals. Crohn’s disease is one of the inflammatory bowel diseases. Its incidence is significantly rising in Ireland. Concomitant association of NF1 and Crohn’s disease is a rare finding. This is the first case reported in the paediatric population.

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More